Insmed is developing and investigating treatments for rare lung diseases. Current product candidates utilize proprietary technology designed specifically for delivery of pharmaceuticals to the lung.

Product Pipeline

PreclinicalPhase 1Phase 2Phase 3Approved
  • ARIKAYCE® (Amikacin Liposome Inhalation Suspension)*

    Refractory NTM: M. avium complex (MAC)    
    Phase 3 93%
  • ARIKAYCE® (Amikacin Liposome Inhalation Suspension) Lifecycle Management

    Front line, maintenance, other non-MAC NTM species, e.g., M Abscessus    
    Phase 3 60%
  • INS1007: DPP1 Inhibitor

    Non-CF bronchiectasis  
    Phase 2 48%
  • INS1009: Inhaled Prostanoid

    Pulmonary Arterial Hypertension (PAH)  
    Preclinical 15%
  • Internal R&D

    Gram-positive lung infections  
    Preclinical 15%
  • Internal R&D

    Refractory biofilm infections  
    Preclinical 15%
  • Internal R&D

    Various indications  
    Preclinical 15%
  • Corporate Development


* As a condition of accelerated approval, Insmed is collaborating with the FDA on the design of an additional clinical study to support full approval. The study design is currently under discussion with FDA and is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with NTM lung disease caused by MAC.